Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN COMBINATION WITH AN INTRAVITREAL ANTI-VEGF AGENT IN SUBJECTS WITH RETINAL VEIN OCCLUSION

Trial Profile

A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN COMBINATION WITH AN INTRAVITREAL ANTI-VEGF AGENT IN SUBJECTS WITH RETINAL VEIN OCCLUSION

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs Triamcinolone (Primary) ; Bevacizumab; Ranibizumab
  • Indications Retinal oedema; Retinal vein occlusion
  • Focus Registrational; Therapeutic Use
  • Acronyms TOPAZ
  • Sponsors Clearside Biomedical
  • Most Recent Events

    • 07 Jan 2019 Status changed from recruiting to discontinued.
    • 23 Dec 2018 This trial was discontinued in Estonia, according to European Clinical Trials Database.
    • 21 Aug 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top